Drug intelligence / Profile preview

131I-AuNPs@PEG-SP94

Development stage
Preclinical
Lead developer
Fudan University
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

131I-AuNPs@PEG-SP94 is a preclinical radiolabeled gold nanoparticle conjugate designed for the targeted treatment of liver cancer (hepatocellular carcinoma). The therapeutic agent consists of gold nanoparticles (AuNPs) modified with thiol-polyethylene glycol (HS-PEG-COOH) and conjugated to the SP94 peptide, which specifically targets glucose-regulated protein 78 (GRP78) overexpressed on the surface of liver cancer cells. The nanoparticles are radiolabeled with iodine-131 (131I) using the chloramine T method. Upon binding to GRP78, the conjugate is internalized, delivering localized beta and gamma radiation from the 131I isotope to induce DNA damage, reactive oxygen species (ROS) accumulation, and apoptosis in tumor cells, while promoting immunogenic cell death.

Other names
131I-labelled gold nanoparticles targeting GRP78131I-labelled gold nanoparticles targeting glucose-regulated protein 78
02

Identity

Drug type
Peptides
Modality
PeptidesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesBeta-minus EmittersGamma EmittersNanoparticles
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
hepatocellular carcinoma (HCC)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Fudan UniversityLead developer
07

Competitive landscape

Drugs on the same target
6
Drugs in the lead indication
966

Lead indication: hepatocellular carcinoma (HCC)

Most advanced in the lead indication

  1. ADC 3Approved
  2. atezolizumabApproved
  3. bevacizumabApproved
  4. cabozantinibApproved
  5. durvalumabApproved

Beyond the preview

Go deeper on 131I-AuNPs@PEG-SP94.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 131I-AuNPs@PEG-SP94.

Work on 131I-AuNPs@PEG-SP94? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call